OVA1 Ovarian Cancer Blood Test Gets FDA Approval

The recent ovarian cancer blood test known as OVA1 received the FDA’s stamp of consent that could aid in detecting ovarian cancer present in the pelvic mass which is previously identified to entail surgery.

During a news broadcast, the FDA stated that this test would be beneficial for both patients and their doctors in choosing who would perform and what would be the form of surgery that needs to be undertaken. However, the OVA1 test is not meant for screening of ovarian cancer and should not be employed for specific ovarian cancer detection.

The FDA stated that the OVA1 test recognizes those set of women that would gain from referral to a gynaecological oncologist for their surgery to be performed in spite of scientific and radiological tests giving negative outcome for ovarian cancer. Despite other test results indicating cancer; being referred to an oncologist is apposite regardless of negative OVA1 test outcome.

The FDA said that the OVA1 test ought to be employed by primary care GP’s or gynaecologists as a complementary testing method that should not be a substitute for other analytical and clinical methods.

During the OVA1 testing, the blood sample is utilised for testing it for levels of five proteins that show variation due to the presence of ovarian cancer. The comprehensive test merges the five separate outcomes into one numerical scoring that lies in the range between 0-10 to signify the probability of whether the pelvic mass is benign or malevolent in nature.

OVA1 is solely designed for 18 years and over women that have already been chosen for surgery due to the presence of the pelvic mass. The information about whether the woman concerned has been menopausal is required to interpret the outcome of the test.

According to the FDA, the suggestions and the subsequent reports published by the American College of Obstetricians and Gynaecologists and the Society of Gynaecologic Oncologists show that ovarian cancer patients had better survival and lowered surgical complications if their surgery is carried out by gynaecologic oncologists rather than by gynaecologists or surgeons.

The FDA approved the OVA1 test on the basis of a study carried out on 516 patients that included 269 patients assessed by non-gynaecological oncologists that put side by side the outcome from OVA1 and biopsy. When gelled with pre-surgical data like radiography and other lab analysis, the outcome from the OVA1 tests recognized further more patients that could reap benefits from oncology referral that weren’t detected by pre-surgical data.

Popularity: 3% [?]